ANAKURIA THERAPEUTICS
Anakuria Therapeutics is a company recently formed by Navitor to advance its novel class of selective rapamycin analog mTORC1 inhibitors.
ANAKURIA THERAPEUTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2021-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Status:
Active
Similar Organizations
Lannett Company
Lannett develops, manufactures, and distributes generic prescription pharmaceutical products in tablet.
Nivalis Therapeutics
Nivalis Therapeutics is a clinical-stage pharmaceutical company developing a novel class of disease modifying therapies.
PSMA Therapeutics
PSMA Therapeutics is a subsidiary of Noria to advance the platform of prostate-specific membrane antigen (PSMA) targeting radiotherapeutics.
thera-LINK
thera-LINK is a HIPAA secure video platform founded by therapists for therapists to allow therapists to meet with their clients online.
Vigeo Therapeutics
Vigeo Therapeutics is a biopharmaceutical company developing novel therapeutic agents intended to treat advanced malignant tumors.
More informations about "Anakuria Therapeutics"
Johnson & Johnson bags rapamycin analog biotech Anakuria
Feb 7, 2022 Anakuria’s lead Phase 1-ready program, AT-20494 provides Janssen with a first-in-class opportunity in autosomal dominant polycystic kidney disease, or ADPKD. AT-20494 is an …See details»
Navitor Pharmaceuticals Announces Janssen Has Acquired …
Of Johnson & Johnson has acquired Anakuria Therapeutics, Inc., (“Anakuria”), a company recently formed by Navitor to advance its novel class of selective rapamycin analog mTORC1 …See details»
Anakuria Therapeutics - PitchBook
Anakuria Therapeutics General Information Description. Operator of a biotechnology firm based in Cambridge, Massachusetts. The company's lead Phase 1 ready program, AT-20494 provides …See details»
Navitor Pharmaceuticals Announces Janssen Has Acquired …
Feb 2, 2022 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Today, privately held Navitor Pharmaceuticals LLC (“Navitor”), announced that Janssen Pharmaceuticals, Inc. (“Janssen”), …See details»
Anakuria Therapeutics - Products, Competitors, Financials, …
Anakuria Therapeutics is a biotechnology company originally formed to advance a novel class of selective rapamycin analog mTORC1 inhibitors. On February 2nd, 2022, Anakuria …See details»
Janssen Acquires Anakuria Therapeutics, Inc.
Feb 2, 2022 Navitor Pharmaceuticals announced that Janssen Pharmaceuticals has acquired Anakuria Therapeutics, Inc., a company recently formed by Navitor to advance its novel class of selective rapamycin analog mTORC1 inhibitors. …See details»
Anakuria Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Explore Anakuria Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, , Technology Platform:Small molecule drug, Drug:AT-20494. ... The statistics for drugs in the …See details»
Janssen acquires Anakuria Therapeutics - 2022-02-02 - Crunchbase
Feb 2, 2022 Anakuria Therapeutics Anakuria Therapeutics is a company recently formed by Navitor to advance its novel class of selective rapamycin analog mTORC1 inhibitors. Acquiring …See details»
New mTOR inhibitor moves forward; acquisition and …
Feb 3, 2022 Today, privately held Navitor Pharmaceuticals, LLC, announced that Janssen Pharmaceuticals, Inc. has acquired Anakuria Therapeutics, Inc., a company recently formed by Navitor to advance its novel class of selective …See details»
Janssen acquires Anakuria Therapeutics | The Pharmaletter
Feb 7, 2022 US healthcare giant Johnson & Johnson’s (NYSE: JNJ) unit Janssen Pharmaceuticals has acquired Anakuria Therapeutics. Anakuria is a company recently formed …See details»
Navitor Pharmaceuticals Announces Janssen Has Acquired …
Feb 2, 2022 Today, privately held Navitor Pharmaceuticals, LLC (“Navitor”), announced that Janssen Pharmaceuticals, Inc. (“Janssen”), one of the Janssen Pharmaceutical Companies of …See details»
Anakuria Therapeutics | CipherBio
Explore Anakuria Therapeutics's investment information, scientific platforms, therapeutic approaches, indications and more here!See details»
Navitor Pharmaceuticals Announces Janssen Has Acquired …
Feb 2, 2022 Anakuria’s lead Phase 1 ready program, AT-20494 provides Janssen with a first-in-class opportunity in autosomal dominant polycystic kidney disease, or ADPKD. This deal was …See details»
Navitor Pharmaceuticals Announces Janssen Has Acquired …
Feb 4, 2022 Under the terms of the agreement, Janssen has acquired all outstanding shares of Anakuria, which is now a wholly owned subsidiary of Janssen. Tom Hughes, president and …See details»
Anakuria Therapeutics - Tech Stack, Apps, Patents & Trademarks
Organization. Anakuria Therapeutics . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. Patents and Trademarks by IPqwery. Edit Patents and …See details»
Anakuria Therapeutics, Inc. (Anakuria Therapeutics, Inc.) - 药物管 …
了解Anakuria Therapeutics, Inc. (Anakuria Therapeutics, Inc.)公司的药物管线，治疗领域，技术平台，以及它的1篇新闻，技术平台:小分子化药，药物:AT-20494。See details»
Navitor Pharmaceuticals Announces Janssen Has Acquired …
Feb 2, 2022 The Life Sciences team advised Navitor Pharmaceuticals, LLC on Janssen Pharmaceuticals, Inc.’s acquisition of Anakuria Therapeutics, Inc.. Navitor is the leader in the …See details»
Oracle and NVIDIA Collaborate to Help Enterprises Accelerate …
5 days ago Oracle and NVIDIA today announced a first-of-its-kind integration between NVIDIA accelerated computing and inference software with Oracle’s AI infrastructure and generative …See details»
Navitor Pharmaceuticals Announces Janssen Has Acquired …
Feb 2, 2022 CAMBRIDGE, MA, USA I February 02, 2022 I Today, privately held Navitor Pharmaceuticals, LLC (“Navitor”), announced that Janssen Pharmaceuticals, Inc. (“Janssen”), …See details»